Physician profile

Anne M Klassert

Adult Health (Nurse Practitioner) · Stony Brook, NY

NPI 1467448985

$7,185.18

in general payments reported to CMS, 2019-2025

44 companies · $1,954 in 2025

The $1,954 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,066.81
Education$8.60

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Biotech, INC. $1,125.73 2021-2025 Erleada, Rybrevant, Carvykti
Urogen Pharma, INC. $635.89 2022-2025 Jelmyto
Bayer Healthcare Pharmaceuticals INC. $523.92 2022-2025
Astellas Pharma US INC $416.19 2021-2024 Myrbetriq, Xtandi
Myriad Genetic Laboratories, INC. $387.28 2021-2025 Prolaris, Myrisk
Coloplast Corp $350.72 2021-2025 Speedicath
Blue Earth Diagnostics $308.19 2021-2025 Posluma
Abbvie INC. $266.36 2022-2025
Amgen INC. $246.98 2024-2025 Repatha, Uplizna
Astrazeneca Pharmaceuticals Lp $236.63 2023-2025 Andexxa, Airsupra
Teleflex LLC $212.51 2025 Urolift
Janssen Pharmaceuticals, INC $190.83 2022
180 Medical, INC. $174.97 2024 Gentlecath
Genentech USA, INC. $144.47 2022
Biogen, INC. $142.15 2023 Spinraza
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Tactile Systems Technology INC $125.89 2022
Organogenesis INC. $124.99 2023 Puraply Antimicrobial
Janssen Scientific Affairs, LLC $124.94 2022
Idorsia Pharmaceuticals US INC $124.47 2022
Ferring Pharmaceuticals INC. $117.24 2024-2025 Adstiladrin
Inspire Medical Systems, INC. $117.19 2023 Inspire
Sumitomo Pharma America, INC. $100.25 2023-2025 Gemtesa
Advanced Oxygen Therapy INC. $87.32 2023 Topical Oxygen Chamber For Extremities
Tolmar, INC. $81.87 2023-2025 Eligard
Telix Pharmaceuticals $81.45 2024-2025 Illuccix
Neurelis, INC. $81.03 2024 Valtoco
Hollister Incorporated $75.20 2022-2023 Infyna Chic, Vapro Plus Pocket, Vapro
Laborie Medical Technologies Corp. $70.43 2025 Optilume Bph Drug Coated Balloon Catheter
Dentsply Ih Ab $68.61 2023-2025 Lofric, Lofric
Endo Pharmaceuticals INC. $63.12 2022
Tolmar Pharmaceuticals, INC. $58.36 2021
Alnylam Pharmaceuticals INC. $49.07 2021-2023 Oxlumo
Pfizer INC. $48.07 2021-2024
Myovant Sciences INC. $35.83 2021-2022
Photocure INC $27.07 2024 Cysview
Urovant Sciences INC $21.17 2022
Immunitybio, INC. $20.98 2025
Clarus Therapeutics INC. $20.79 2021
Progenics Pharmaceuticals, INC. $19.58 2025
Provepharm INC. $18.03 2025 Bludigo
Dentsply Ih INC. $17.09 2021
Endo USA, INC. $16.68 2025 Aveed, Xiaflex
Civco Medical Instruments $13.88 2024
Olympus America INC. $11.76 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anne M Klassert

$7,185.18

in general payments reported 2019-2025

Years
2021-2025
Top company
Janssen Biotech, INC.
Context
The $1,954 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).

https://glasscript.com/doctor/10773713/anne-m-klassert

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.